Vantage Investment Partners LLC Invests $22.35 Million in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Vantage Investment Partners LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 53,217 shares of the company's stock, valued at approximately $22,348,000. IDEXX Laboratories makes up approximately 1.9% of Vantage Investment Partners LLC's holdings, making the stock its 21st largest holding. Vantage Investment Partners LLC owned about 0.07% of IDEXX Laboratories as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sagespring Wealth Partners LLC bought a new position in shares of IDEXX Laboratories during the first quarter valued at $229,000. Banque Transatlantique SA bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $2,681,000. Steward Partners Investment Advisory LLC raised its holdings in shares of IDEXX Laboratories by 9.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,436 shares of the company's stock valued at $1,007,000 after buying an additional 218 shares during the last quarter. NEOS Investment Management LLC raised its holdings in shares of IDEXX Laboratories by 14.8% in the fourth quarter. NEOS Investment Management LLC now owns 7,014 shares of the company's stock valued at $2,900,000 after buying an additional 904 shares during the last quarter. Finally, Assetmark Inc. raised its holdings in shares of IDEXX Laboratories by 83.4% in the fourth quarter. Assetmark Inc. now owns 33,804 shares of the company's stock valued at $13,976,000 after buying an additional 15,377 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Stifel Nicolaus lifted their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Morgan Stanley lifted their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Finally, Leerink Partners lifted their price target on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $546.00.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,046 shares of the business's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $513.74, for a total transaction of $537,372.04. Following the completion of the transaction, the director now directly owns 262 shares in the company, valued at approximately $134,599.88. The trade was a 79.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $523.92 on Friday. The stock has a 50-day moving average price of $486.81 and a 200 day moving average price of $447.73. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. The firm has a market cap of $42.13 billion, a price-to-earnings ratio of 48.42, a PEG ratio of 3.83 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $530.73.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The company's revenue was up 3.6% on a year-over-year basis. During the same period last year, the company earned $2.71 earnings per share. Research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.